2010 Scrip 100 - Can China retain its API sourcing appeal?
This article was originally published in Scrip
Executive Summary
China has a burgeoning API manufacturing base, albeit one focused largely on achieving quick profits in the domestic sector. Robert Kennedy's analysis reveals a striking number of Chinese companies that are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
You may also be interested in...
Commentary: China's changing role in the global pharmaceutical supply chain
In preparation for the 2008 Olympic and Paralympic games, the Chinese government shut down a large number of factories in and around Beijing in an effort to improve the air quality for the athletes and spectators. With the implementation of more stringent environmental health and safety (EHS) regulations, many of these factory closures will be permanent because the facilities cannot conform to new waste water treatment standards. In the past, the Chinese government would not have shut down a major manufacturer and tax generator just because they did not meet all of the EHS requirements.